ebm.bmj

Ataluren for Duchenne: how politics and social pressure undermined evidence-based decisions

Last 28 March 2025, the European Commission decided not to renew the conditional marketing authorisation for Translarna (ataluren) in Duchenne’s disease due to lack of efficacy after 11 years in the ...
ebm.bmj

Using individual participant data to improve network meta-analysis projects

A network meta-analysis combines the evidence from existing randomised trials about the comparative efficacy of multiple treatments. It allows direct and indirect evidence about each comparison to be ...
ebm.bmj

Survey of instructions for authors on how to report an update of a systematic review: guidance is needed

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
ebm.bmj

Assessing allocation concealment and blinding in randomised controlled trials: why bother?

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
ebm.bmj

7 How should we communicate about overdiagnosis? When we talk about overdiagnosis, what do people hear?

Overdiagnosis researchers and advocates care about the challenging and counterintuitive problem of overdiagnosis, and many are keen to inform others about the problem. Literature review suggests ...
ebm.bmj

029 Assessment of shared decision-making levels with the option-5: a systematic review after 10 years of use

Introduction In 2013, the Observing Patient Involvement in Decision Making instrument (OPTION-5) was developed to measure levels of shared decision-making (SDM) in consultations. 1 Since then, it has ...
ebm.bmj

075 Measuring healthcare provessionals’ perceptions of their ability to adopt shared decision making: translation and psychometric evaluation of the Danish version of the ...

1 Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark 2 Department of Clinical Medicine, Aarhus University, Aarhus, Denmark 3 Leeds Unit of Complex Intervention Development, ...
ebm.bmj

Improving inclusivity in UK clinical trials through good practice in the collection and use of ethnicity data: recommendations from the INCLUDED study

Ethnicity data are essential in understanding how different groups are impacted by different treatments/healthcare interventions, but more work is needed in how these data should be collected, handled ...
ebm.bmj

Cluster-randomised controlled trials

As a public health practitioner, you are considering how public health interventions might encourage individuals and families to reduce their salt intake to improve blood pressure among local ...
ebm.bmj

Equity and representativeness in pragmatic drug trials: methodological and ethical considerations

The WHO defines health equity as ‘the absence of unfair, avoidable or remediable differences among groups of people based on various dimensions of inequality (eg, sex, gender, ethnicity, disability or ...
ebm.bmj

Defining and interpreting the clinical relevance of intervention effects for patient-reported outcomes: the smallest worthwhile effect construct

In clinical research, statistically significant effects do not necessarily indicate that an intervention provides benefits that are meaningful to patients. This is particularly important for ...
ebm.bmj

Educating health professionals in evidence-based practice in 2026

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...